Davis' comments on Tuesday echo those from January, when he said showing outcomes for cardiovascular, diabetes and conditions other than weight management would make it easier for drugs to get insurance reimbursements.
The weight-loss drug market is estimated to be worth about $150 billion in annual global sales by the early 2030s and is currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both belonging to the GLP-1 class.
GLP-1 drugs, which help slow digestion and reduce hunger by triggering a feeling of fullness, are now being studied to see whether they can improve health in other ways.
Merck said earlier this year that it was seeking GLP-1 treatments with benefits beyond weight loss as the drugmaker develops its own candidate, efinopegdutide, for a type of serious fatty liver disease now known as metabolic dysfunction-associated steatohepatitis (MASH).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.